MPGN type I induced by granulocyte colony stimulating factor.

Abstract

We report a girl with severe congenital neutropenia who has received long-term granulocyte-colony stimulating factor (G-CSF) therapy and has developed macroscopic hematuria, proteinuria, and decreased renal function associated with biopsy-proven membranoproliferative glomerulonephritis (MPGN) type I. Temporary discontinuation of G-CSF therapy as well as the use of glycosylated G-CSF has resulted in improvement in renal manifestations. We postulate that the MPGN was G-CSF-induced. Long-term G-CSF therapy should be used with great caution and close surveillance of kidney function.

• Authors: Daniella Magen, Hana Mandel, Moshe Berant, Ofer Ben-Izhak, Israel Zelikovic
• Journal: Pediatric nephrology (Berlin, Germany) (Pediatr Nephrol) Vol. 17 Issue 5 Pg. 370-2 (May 2002) ISSN: 0931-041X [Print] Germany
• PMID: 12042897 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor
• Lenograstim

Topics

• Adjuvants, Immunologic (therapeutic use)
• Adolescent
• Drug Administration Schedule
• Female
• Glomerulonephritis, Membranoproliferative (chemically induced, pathology)
• Granulocyte Colony-Stimulating Factor (administration & dosage, adverse effects, therapeutic use)
• Humans
• Lenograstim
• Neutropenia (congenital, drug therapy)
• Recombinant Proteins (therapeutic use)
• Retreatment